{"id":"W3008910065","doi":"10.1200/jco.2020.38.15_suppl.tps5095","title":"PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible <i>FGFR3</i> alterations.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Clinical endpoint; Cisplatin; Placebo; Internal medicine; Oncology; Adjuvant therapy; Chemotherapy; Urology; Gastroenterology; Clinical trial; Adverse effect; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001491668,0.002022012,0.002945891,0.000382668,0.0003506871,0.00103395,0.001028255,0.001677913,0.007719626],"category_scores_gemma":[0.001460601,0.0006635929,0.001615977,0.0003563194,0.0009712943,0.001244633,0.0003825641,0.002693467,0.001392569],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006114828,"about_ca_system_score_gemma":0.001474231,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007369561,"about_ca_topic_score_gemma":0.001989404,"domain_scores_codex":[0.9995729,0.0001957341,0.00002808245,0.00009697139,0.00003766537,0.00006853374],"domain_scores_gemma":[0.9994455,0.0001208891,0.0001421693,0.00003995069,0.0000512469,0.0002002412],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.972481,0.006374386,0.0002399181,0.001367423,0.0006374678,0.0000447352,0.00004340775,0.0003079393,0.004479967,0.0002036603,0.0015217,0.01229846],"study_design_scores_gemma":[0.9551856,0.0430044,0.0004117792,0.00002783005,0.0001670009,0.00003620672,0.00001307602,0.0002242156,0.0002528655,0.000116918,0.0005498047,0.00001015593],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9547846,0.0126331,0.001608164,0.001785879,0.001819373,0.01699307,0.004286952,0.0006403359,0.005448438],"genre_scores_gemma":[0.960996,0.005788476,0.003450915,0.002794199,0.0005401064,0.01636531,0.003539675,0.0000660125,0.006459311],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007719626,"threshold_uncertainty_score":0.02582473,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0946758322408685,"score_gpt":0.4131305022468749,"score_spread":0.3184546700060064,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}